Results 111 to 120 of about 4,006,149 (207)

Translating gut microbiome research into therapies for type 1 diabetes

Experimental Physiology, EarlyView.
Abstract Type 1 diabetes (T1D) is characterised by the loss of functional pancreatic β‐cells, for which lifelong insulin therapy remains the standard of care. Given that the gut microbiome can influence host health and that shifts in gut microbial profiles have been observed in T1D, growing interest has emerged in the role of the gut microbiome in T1D,
Shanti P. Kok, Max Nieuwdorp, Elena Rampanelli   +2 more
wiley   +1 more source

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

International Journal of Cancer, Volume 159, Issue 8, Page 1857-1872, 15 October 2026.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang, Hui Wang, Weiyan Tang, Kai Kang, Kateryna Onyshchenko, Taotao Huang, Dan Liu, Jianxin Xue, You Lu, Gabriele Niedermann, Ren Luo   +10 more
wiley   +1 more source

Microbiome‐Derived Tryptophan Metabolites Regulate AhR Signaling to Restore Epithelial Barrier Integrity in Inflammatory Bowel Disease

MicrobiologyOpen, Volume 15, Issue 5, October 2026.
The graphical abstract illustrates how microbiome‐derived indoles activate the aryl hydrocarbon receptor to restore the intestinal barrier. The picture contrasts the “leaky gut” state with the restored homeostasis achieved through AMPK, Nrf2, and IL‐22 signaling.
Mohammad Ali Mahdiabadi, Asma Moghaddam, Nafiseh Erfanian   +2 more
wiley   +1 more source

278O Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295

Annals of Oncology, 2022
J. Campian, O. Butt, J. Huang, J. Luo, Y. Tao, R. Strowd, D. Hissim, S. Kizilbash, C. Abraham, G. Ansstas, T. Johanns, A. Kim, M. Ciorba, M. Chheda   +13 more
semanticscholar   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, Volume 270, Issue 2, Page 139-162, October 2026.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

The evolving role of immunotherapy in ovarian cancer

Cancer, Volume 132, Issue 18, 15 September 2026.
Abstract Ovarian cancer remains a major cause of gynecologic cancer mortality; and, although immune checkpoint inhibitors have transformed treatment in other solid tumors, their activity in ovarian cancer has been limited by tumor heterogeneity, an immunosuppressive tumor microenvironment, and the lack of robust predictive biomarkers.
Ana Carolina Veneziani, Laura Venegas, Amit M. Oza   +2 more
wiley   +1 more source

Az indolamin-2,3-dioxigenáz-1 (IDO1) enzim farmakogenomikai vizsgálata humán tumorokban

Az indolamin-2,3-dioxigenáz-1 (IDO1) enzim a triptofán (Trp) lebontás első, sebességmeghatározó lépését katalizálja. A magas IDO1 szintnek, illetve a Trp metabolitok megnövekedett szintjének immunmoduláló és immunszuppresszív hatása van.
Hornyák, Anna
core  

Targeting a Myeloid–Regulatory B Cell Network Reverses Immune Paralysis in Periprosthetic Joint Infections

Advanced Science, Volume 13, Issue 51, 14 September 2026.
Periprosthetic joint infection establishes a sophisticated immunosuppressive network between CXCR4+ PMN‐MDSCs and Bregs, inducing profound CD8+ T cell paralysis. Alendronate effectively disrupts this CXCR4+ PMN‐MDSC–Breg axis by targeting STAT3, thereby restoring local immune surveillance.
Jintao Wu, Shutao Zhang, Yumin Lin, Juyang Jiao, Zhiwei Fu, Qimin Hong, Ziyi Zhao, Xinhua Qu, Fei Su, Bing Yue   +9 more
wiley   +1 more source

Role of indoleamine 2, 3-dioxygenase 1 in immunosuppression of breast cancer

Cancer Pathogenesis and Therapy
Breast cancer (BC) contributes greatly to global cancer incidence and is the main cause of cancer-related deaths among women globally. It is a complex disease characterized by numerous subtypes with distinct clinical manifestations.
Pratyasha Sarangi
doaj   +1 more source

Slc44a2 Deficiency Unveils an IFN‐I–Dependent Feedback Control of pDC Egress

Advanced Science, Volume 13, Issue 53, 24 September 2026.
Working model of SLC44A2‐mediated maintenance of pDC homeostasis. This model illustrates two central mechanisms by which SLC44A2 regulates pDC homeostasis: (1) SLC44A2 limits IFN‐I production by exporting amino acids (T, N, Q), thereby preventing spontaneous pDC activation.
Ruiqun Chen, Tao Wu, Zhen Shi, Ravi Kumar Verma, Linlin Sheng, Lei Tao, Mingming Yang, Yuchen Wang, Conggang Zhang, Hao Fan, Li Wu, Ligong Chen   +11 more
wiley   +1 more source